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Abstract
In randomized experiments with noncompliance, tests may focus on compliers rather than
on the overall sample. Rubin (1998) put forth such a method, and argued that testing for the
complier average causal effect and averaging permutation based p-values over the posterior dis-
tribution of the compliance status could increase power, as compared to general intent-to-treat
tests. The general scheme is to repeatedly do a two-step process of imputing missing compliance
statuses and conducting a permutation test with the completed data. In this paper, we explore
this idea further, comparing the use of discrepancy measures, which depend on unknown but
imputed parameters, to classical test statistics and exploring different approaches for imputing
the unknown compliance statuses. We also examine consequences of model misspecification in
the imputation step, and discuss to what extent this additional modeling undercuts the permu-
tation test’s model independence. We find that, especially for discrepancy measures, modeling
choices can impact both power and validity. In particular, imputing missing compliance statuses
assuming the null can radically reduce power, but not doing so can jeopardize validity. Fortu-
nately, covariates predictive of compliance status can mitigate these results. Finally, we compare
this overall approach to Bayesian model-based tests, that is tests that are directly derived from
posterior credible intervals, under both correct and incorrect model specification. We find that
adding the permutation step in an otherwise Bayesian approach improves robustness to model
specification without substantial loss of power.
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1 Introduction
Noncompliance refers to the situation when the actual treatment received does not perfectly cor-
respond to treatment assigned in a randomized experiment. With noncompliance, a simple intent-
to-treat analysis, which compares outcomes based on the assignment, can fail to estimate the effect
of the treatment itself. The usual approach in these circumstances is to use instrumental variables
(IV)(Imbens & Angrist, 1994; Angrist et al., 1996), which can be thought of as a special case of
principal stratification (Frangakis & Rubin, 2002), where the units are partitioned into subpopula-
tions defined by the compliance behavior, and where the focus is then on the effect of the treatment
among compliers, i.e., those who would always comply to the treatment assigned irrespective of the
arm. This subpopulation effect is often referred to as the complier average causal effect (CACE).
In an IV analysis, identification of such effect hinges on the absence of defiers (monotonicity as-
sumption) and the lack of any effect of the assignment for noncompliers (the exclusion restriction
assumption). Under these assumptions, a zero intent-to-treat effect (ITT) is a necessary and suf-
ficient condition for CACE being zero as well. Therefore, a hypothesis test for ITT will be a valid
test to assess a zero treatment effect for compliers. Nevertheless, ITT tests ignore all compliance
information. This is where Rubin (1998) attempted to obtain more power by focusing on testing
procedures that incorporate compliance information. This was motivated by the observation that,
taking the presence of noncompliance into account, rather than just estimating an overall average
effect, would exploit the information of the data to a larger extent. On the other hand, such a test
seems challenging to construct because the compliance status is typically not known for all units.
Rubin’s proposal was to average p-values over the posterior predictive distribution of the vector
of compliance statuses. Under an MCMC perspective this translates into including an imputation
or data augmentation step, where each unit’s compliance status is imputed from its posterior
predictive distribution and then a p-value for the complier effect is generated from the complete
data within each MCMC iteration. This Bayesian approach to p-values has its roots in the posterior
predictive model-checking method (Guttman, 1967; Rubin, 1981, 1984), a popular model-checking
tool that can account for nuisance parameters by comparing the observed data to synthetic data
drawn from the posterior predictive distribution of a hypothesized model marginalized over the
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nuisance parameters. Meng (1994) and Gelman et al. (1996) extended posterior predictive checks
by replacing classical test statistics with discrepancy variables, that is, variables that depend on the
nuisance parameters, and this extension can also be applied to testing. Finally, Rubin (1998) applied
the idea of Bayesian posterior p-values to Fisher randomization tests (Fisher, 1925, 1926, 1935)
for experimental designs in the presence of noncompliance. Fisher randomization tests (FRTs),
or permutation tests, are nonparametric tests that can be used to test a null hypothesis on the
outcome distribution of a randomized experiment. The reference distribution of a test statistic is
derived by computing its value for each possible permutation of the assignment vector under the
known assignment mechanism.
In this paper, we explore this general idea of posterior predictive Fisher randomization tests
more in depth, and conduct extensive simulation studies to show how these tests play out in practice
in randomized experiments with noncompliance. The combination of Fisher randomization tests
with posterior predictive p-values lead to a sequence of both a permutation and an imputation step.
At each iteration, a test statistic, in its classical view, is computed from the data that would have
been observed under the permuted assignment vector and the imputed compliance status vector.
Rubin (1998) proposed the use of any estimator of the complier average casual effect as classical tests
statistic. Here, we first examine the replacement of such test statistics with discrepancy measures.
In noncompliance settings, a discrepancy measure for obtaining posterior predictive FRTs would
be an estimate of CACE conditional on the imputed compliance statuses. These measures seem
promising because they can directly estimate CACE from the complete data. We investigate the
benefits and disadvantages of using discrepancy measures for testing as compared to test statistics.
We also closely examine the imputation step. Different methods are possible, such as imputing
under the null or under the alternative. Imposing the null seems a natural choice from a testing ap-
proach, and is also in line with posterior predictive checks, where nuisance parameters are typically
drawn from the assumed model. Imposing the null also protects the validity of the overall testing
procedure. However, this approach turns out to have some potential costs in terms of power. We
explore this, and discuss how to mitigate these costs.
The imputation step without the permutation step is nothing more than what would typically
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be used for the direct estimation of the posterior distribution of CACE. Credible intervals of
this posterior distribution could themselves lead to nominal p-values. These model-based p-values
are less computationally demanding than the posterior predictive p-values obtained by a Fisher
randomization test within the imputation step. We compare these two approaches, and see if the
addition of the Fisher randomization test has anything extra to offer. In particular, we compare
the performance of these two testing methods under both correct and incorrect model specification.
Simulation studies suggest several “best practices” as well as help elucidate the reasons of why each
approach can work.
Finally, we discuss how predictive covariates are of particular importance for the performance of
discrepancy-based FRTs. Predictive covariates help alleviate model misspecification concerns which
can arise in the imputation step, and help address many of the concerns found in our investigations.
The paper is organized as follows. In Section 2, we give a brief review of posterior predictive
checks. We then introduce Fisher randomization tests in Section 3 and illustrate the use of posterior
predictive p-values to deal with the unknown compliance status in noncompliance settings. In
Section 4, we describe the simulation studies we constructed to compare the use of discrepancy
measures versus tests statistics, assess the impact of different modeling assumptions, and determine
the potential benefits of predictive covariates. Simulation results are shown in Section 5. In
Section 6 we compare the validity of FRTs in combination with posterior predictive p-values to the
corresponding Bayesian model-based tests. We discuss common patterns and what they suggest
for practice, in Section 7.
2 Posterior Predictive Checks
Classical p-values were extended to the Bayesian framework by Guttman (1967) and Rubin (1981,
1984). The Bayesian framework is particularly appealing for investigating the compatibility of a
posited model with observed data when the model has unknown nuisance parameters (composite
null model). While classical method would typically plug-in a point estimate of the parameter and
rely on known reference distributions of pivotal quantities or on asymptotic results, Bayesian tests
average over the posterior distribution of the unknown parameters and use the posterior predictive
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distribution to simulate the reference distribution for any test statistic.
Suppose we have a realization Y obs of a random variable Y and we posit a parametric null
model, H0 : Y ∼ f(Y | θ),θ ∈ Θ0. The essence of model assessment lies in comparing the ob-
served data with hypothetical replicates that could be observed under the assumed model. The
classical approach amounts to measuring the discrepancy between the observed value of a test
statistic, T (Y obs), and its reference (i.e., sampling) distribution derived under the posited model.
A Bayesian model checking approach uses the posterior predictive distribution under the null hy-
pothesis, p(Y |Y obs, H0), to derive the posterior distribution of the test statistic. Assuming a test
statistic T (Y obs) where larger values contraindicate the null, the posterior predictive p-value based
on the test statistic, pBT , is then
pBT =PrY
{
T (Y ) ≥ T (Y obs) | Y obs, H0
}
=Eθ
{
PrY
{
T (Y ) ≥ T (Y obs) | Y obs, H0, θ
}
| Y obs, H0
}
.
(1)
The presence of unknown parameters has been taken into account by averaging over their posterior
distribution under the null hypothesis. A Monte-Carlo simulation-based approach would draw K
values of the parameters, {θk; k = 1, . . . ,K}, from their posterior distribution pi(θ|Y obs, H0),
simulate replications of the data under the conditional distribution f(Y | θk) and compare the
new values of the test statistic with the observed value. This approach follows from an equivalent
expression of equation (1):
pBT =
∫
θ∈Θ0
∫
Y
1
[
T (Y ) ≥ T (Y obs)]f(Y | θ)pi(θ | Y obs, H0)dY dθ (2)
where 1[·] is the indicator function.
Meng (1994) and later Gelman, Meng and Stern (1996) proposed to replace classical test statis-
tics, T (Y ), with parameter-dependent statistics, D(Y ,θ), referred to as discrepancy variables.
These cannot translate to the classical framework because the parameter values are unknown. In
the Bayesian framework, however, they can be used as the posterior gives us predictions for these
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parameters and so both the “observed” discrepancy variables as well as its reference distribution
can be calculated. In particular, the posterior predictive p-value based on a discrepancy variable,
pDT , is
pBD =Eθ
{
PrY
{
D(Y ,θ) ≥ D(Y obs,θ) | Y obs, H0,θ
}
| Y obs, H0
}
=
∫
θ∈Θ0
∫
Y
1
[
D(Y ,θ) ≥ D(Y obs,θ)]f(Y | θ)pi(θ | Y obs, H0)dY dθ. (3)
Note how both D(Y ,θ) and D(Y obs,θ) are random under the posterior distribution. This approach
has two advantages. First, a discrepancy variable requires smaller computational effort than a test
statistic, given that the latter often involves an additional estimation of the parameters. Second,
classical test statistics are typically computed by plugging-in an estimate of the nuisance parameter,
thus they assess the ‘discrepancy’ between the data and the best fit of the model. Conversely, the
use of a parameter-dependent statistic directly checks the ‘discrepancy’ between the data and the
overall model.
Meng (1994) and Robins et al. (2000) derived several results on the frequency evaluation of
discrepancy p-values under the null. If D(Y ,θ) is a pivotal quantity with known distribution D0
under the null, then the distribution of p-values under the null would still be uniform and their
expression would simplify to pBD = Pr
{D0 ≥ D(Y obs, E[θ | Y obs, H0])}. On the other hand, in
the more common situation where the discrepancy is not a pivotal quantity, averaging over the
parameters on which the discrepancy depends leads to a distribution of p-values that is no longer
uniform. Meng investigates the behavior of such p-values under the prior predictive distribution
conditional on the null, i.e., p(Y | H0). His main result is that, under this distribution, discrepancy
p-values are centered around 12 , i.e., EY {pBD | H0} = 1/2 and that PrY {pBD ≤ α | H0} ≤ 2α.
This means that there are cases in which p-values are conservative and other cases in which they
are anti-conservative, but there is a bound for the Type I error of twice the nominal level. His
further discussion suggests, however, that in practice we would expect error rates to rarely be this
high. As the posterior p-values are stochastically less variable than U [0, 1], we expect the tails to
be lighter, and the error rates to often be conservative for low values of α.
Extending this work, Robins et al. (2000) show that discrepancy-based p-values can be seriously
conservative even when the discrepancy has asymptotic mean 0 for all values of the nuisance
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parameters, whereas posterior predictive p-values based on test statistics are conservative whenever
the asymptotic mean of the test statistic depends on the parameters. Arguably, the conservativeness
of a test is not a bad thing per se, because it means that it would not reject a true hypothesis
more often than indicated by the nominal level. Indeed, such tests are considered valid (Neyman,
1934), as the Type I error would be less or equal to α. According to Rubin (1996a), the typical
conservativeness when using discrepancies, noted by Meng (1994) and Gelman et al. (1996), arises
from the ‘extra’ information carried by the imputations of θ. This information can be traced to
both modeling and structural assumptions used to define the posterior distributions used for the
imputation; a fundamental role is played by the the fact that imputations are performed under the
null hypothesis. This argument can be connected to the one for potential conservatism of multiple
imputation in Rubin (1996b), where these informative imputations are called ‘superefficient’.
3 Fisher Randomization Tests using Posterior Predictive p-values
Fisher (1925, 1926, 1935) proposed a distribution-free technique to test a sharp null hypothesis of
zero treatment effect at the unit level for randomized experiments. Rubin (1984) then showed how
these Fisher’s randomization tests (FRTs) can be formally viewed as a posterior predictive check.
The Bayesian justification is that they are based on the posterior predictive distribution of the test
statistic induced by the random assignment Z. Although Fisher never used the potential outcomes
framework—a method of articulating causal effects originally proposed by Neyman in the context
of randomized experiments (Neyman, 1923) and then formalized and extended to observational
studies by Rubin (Rubin, 1974, 1978)—FRTs can be phrased in terms of potential outcomes.
Under the potential outcome framework, the potential outcomes, denoted Yi(1) and Yi(0), rep-
resent the outcomes for individual i had he received the treatment (Zi = 1) or control (Zi = 0)
respectively. Let Zobsi be the treatment that was actually assigned to unit i. The “fundamen-
tal problem of causal inference” (Holland, 1986) is that, for each individual, we can observe only
one of these potential outcomes, i.e., Y obsi = Yi(1)Z
obs
i + Yi(0)(1 − Zobsi ), because each unit will
receive either treatment or control. As first formalized in Rubin (1974), all causal effects are
inherently a comparison of potential outcomes. Thus, Fisher’s sharp null hypothesis H0 of no
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treatment effect can be formalized as Yi(0) = Yi(1) ∀i and Fisher’s p-values can be stated as
PrZ
{
T (Y (Z),Z) ≥ T (Y obs,Zobs) | Zobs,Y obs, H0
}
. Fisher’s hypothesis is said to be sharp be-
cause it allows one to perfectly impute Yi(1 − Zi) for any value of Zi (i.e., the missing potential
outcome).
Rubin (1998) then formalized the idea of Fisher randomization-based tests using posterior
predictive p-values (FRT-PP) in the context of noncompliance. Let Di be the actual treatment
received by unit i; with noncompliance Di may differ from Zi. The compliance type for each unit
is then defined by the joint values of the treatment receipt if assigned to control, Di(0), or to
treatment Di(1). Because we can never observe both Di(0) and Di(1), however, the compliance
status is not generally known for all units. These are the unknown variables we will average
over to obtain posterior predictive p-values. Rubin (1998) took this approach for the case of one-
sided noncompliance, where Di(0) = 0 for all units. With one-sided noncompliance, we have two
compliance types: ‘compliers’, for whom Di(1) = 1 and ‘never-takers’, for whom Di(1) = 0. In
this case compliance statuses are unknown only for those units in the control arm. We also discuss
one-sided noncompliance.
Let Ci denote the compliance status indicator, being 0 for a never-taker or 1 for a complier.
The complier average causal effect (CACE) can then be written as
CACE := E[Yi(1)− Yi(0)|Ci = 1] (4)
. Assuming the exclusion restriction for non-compliers, i.e., Yi(0) = Yi(1) ∀i : Ci = 0, the null
hypothesis we wish to test here is a null effect for compliers, i.e., H0 : Yi(0) = Yi(1) ∀i: Ci = 1. It is
worth noting that, in one-sided noncompliance settings under the exclusion restriction, CACE can
be expressed as the ratio between the intent-to-treat effect, i.e., ITT = E[Yi(1) − Yi(0)], and the
probability of being a complier, i.e, pic = Pr(Ci = 1). Therefore, in principle a rejection of a zero
ITT would necessarily mean a rejection of a zero CACE. The goal of Rubin (1998) was to show
that in some circumstances tests that take noncompliance into account can be more powerful than
the ones based on the ITT only.
Rubin proposed the use of a test statistic T , which depends on the observed data O(Z) for each
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assignment vector Z, with O(Z) = [Y (Z),D(Z),Z], and not on the imputed compliance statuses.
Test statistics can be any estimator of the complier average causal effect (CACE): posterior mean,
posterior median or posterior mode as well as MLE or IV estimates. Regardless of the choice,
the Bayesian procedure averages p-values over the posterior predictive distribution of the unknown
compliance statuses, p(C | Y obs,Dobs,Zobs, H0), which will in turn depend on other unknown
parameters:
pBT = Eθ
{
EC
{
pBT (C) | Y obs,Dobs,Zobs,θ
}
| Y obs,Dobs,Zobs, H0
}
, (5)
where
pBT (C) = PrZ
{
T (Y (Z),D(Z),Z) ≥ T (Y obs,Dobs,Zobs) | Y obs,Dobs,Zobs,C, H0
}
= PrZ
{
T (Y obs,CZ,Z) ≥ T (Y obs,Dobs,Zobs) | C
}
.
The last expression follows from two observations: (1) under the null hypothesis Yi(Zi) is equal to
the observed outcome; and (2) Di(Zi) = CiZi thanks to the definition of the compliance status Ci
in one-sided noncompliance settings.
We can also use the equivalent expressions of
pBT =
∫
θ∈Θ
∫
C
∫
Z
[ ∫
Y (Z)
∫
D(Z)
1
[
T
(
Y (Z),D(Z),Z
) ≥ T (Y obs,Dobs,Zobs)]×
p(Y (Z),D(Z) | Y obs,Dobs,Zobs,C, H0) dY (Z) dD(Z)
]
p(Z)p(C | Y obs,Dobs,Zobs,θ)pi(θ | Y obs,Dobs,Zobs, H0) dZ dC dθ,
(6)
or
pBT =
∫
θ∈Θ
∫
C
∫
Z
1
[
T
(
Y obs,CZ,Z
) ≥ T (Y obs,Dobs,Zobs)]
p(Z)p(C | Y obs,Dobs,Zobs,θ)pi(θ | Y obs,Dobs,Zobs, H0) dZ dC dθ.
(7)
An MCMC approach proceeds, at each iteration k, by first drawing the parameters from their
posterior distribution and then imputing the missing compliance statuses in the control arm using
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the posterior predictive distribution conditional on these draws. Then, for the permutation step,
the assignment vector is permuted and the test statistic computed based on the outcome and
treatment that would be observed under the new assignment vector, if the imputed compliance
statuses were true and the individual treatment effect were null, i.e., T k = T
(
Y obs,CZ,Z
)
. The
p-value pBT is then the proportion of iterations where the test statistic T
k is greater than or equal
to the observed statistic T obs = T
(
Y obs,Dobs,Zobs
)
.
Following Meng (1994) and Gelman et al. (1996), we explore replacing parameter-independent
test statistics with parameter-dependent discrepancy variables. Rubin (1998) already mentioned
the possibility of using discrepancies, such as difference-in-means estimate of the effect among
compliers, i.e. Y 1,c − Y 0,c, but he only used test statistics dependent on O(Z) in his examples.
Compliance-dependent discrepancy p-values can be written as:
pBD = Eθ
{
EC
{
pBD(C) | Y obs,Dobs,Zobs,θ
}
| Y obs,Dobs,Zobs, H0
}
(8)
where
pBD(C) = PrZ
{
D(Y (Z),C,Z) ≥ D(Y obs,C,Zobs) | Y obs,Dobs,Zobs,C, H0
}
= PrZ
{
D(Y obs,C,Z) ≥ D(Y obs,C,Zobs) | C
}
.
In the MCMC, at each iteration the imputed compliance statuses will affect both values of
discrepancy variable, the one for the permuted assignment vector under the null hypothesis, Dk =
D(Y obs,C,Z), and the one for the observed values, Dk,obs = D(Y obs,C,Zobs). pBD is then the
proportion of iterations where Dk ≥ Dk,obs.
Our purpose here is to compare the frequentist performance of FRT-PP based on test statistics
T (Y (Z),D(Z),Z) or on imputed compliance-dependent discrepancy variables D(Y (Z),C,Z). In
particular, we will use the typical IV estimator of CACE (Imbens & Angrist, 1994; Angrist et al.,
1996) as our test statistic:
T (Y (Z),D(Z),Z) =
ÎTT Y
pˆic
=
Y 1 − Y 0
D1 −D0
, (9)
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where ÎTT Y is the method of moments estimator of the effect of the assignment on the outcome,
pˆic is the method of moments estimator of the proportion of compliers,
Y 1 =
∑
i Yi(Zi)Zi∑
i Zi
Y 0 =
∑
i Yi(Zi)(1− Zi)∑
i(1− Zi)
and
D1 =
∑
iDi(Zi)Zi∑
i Zi
D0 =
∑
iDi(Zi)(1− Zi)∑
i(1− Zi)
.
Similarly, the discrepancy variable will be the method of moment estimator of the complier average
causal effect if compliance status were known:
D(Y (Z),C,Z) = Y c1 − Y c0 (10)
where
Y c1 =
∑
i Yi(Zi)CiZi∑
iCiZi
Y c0 =
∑
i Yi(Zi)Ci(1− Zi)∑
iCi(1− Zi)
Based on our previous discussion on the typical conservativeness of discrepancy-based p-values,
we expect the use of these p-values for problems of noncompliance to lead to conservative tests.
Simulations under the null, not shown here, confirm our hypotheses. In fact, in the hypothetical
situation where compliance statuses were known for all units, the distribution of p-values would
still look uniform. On the other hand, when compliance statuses were imputed for units assigned
to control, the distribution of p-values seemed to be concentrated around 0.5. We tested this result
in both the hypothetical case where compliance statuses are imputed from the correct model with
known parameters p(C | Y obs,Dobs,Zobs;θ?) and the more realistic situation where the parameters
are not known. In the latter case, the Bayesian procedure that follows from the definition of p-values
in (5) and (8) uses the posterior predictive distribution of the unknown compliance statuses, which
in turn depends on the posterior distribution of the parameters: p(C | Y obs,Dobs,Zobs, H0) =∫
θ p(C | Y obs,Dobs,Zobs,θ)pi(θ | Y obs,Dobs,Zobs, H0)dθ. Imputation was still conducted under
the correct model. The conservativeness that was seen in this case is presumably due to the fact
that the imputed replications of compliers would carry information on the null hypothesis, given
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that the parameters were estimated under the correct imputation model (consisting of a correct
model specification, the exclusion restriction assumption, and the null hypothesis). In fact, the
discrepancy measure makes use of the information provided by both the data and the model that
is stored in the imputed compliance statuses.
Most of the past literature focuses on the comparison of p-values based on discrepancies and
classical statistics under the null hypothesis. There seems to be less work concerning power. We
should bear in mind that type I error and power are usually traded off against each other: a test
that is less likely to reject a correct hypothesis is usually also less likely to reject an incorrect
one. The purpose of this paper is to shed light on this trade-off for discrepancy-based p-values
in noncompliance settings. Does a reduction in the type I error to below α levels signal a loss of
power? When is this trade-off more of an issue?
Power simulations in the hypothetical case with known parameters and correct (alternative)
model specification showed that discrepancy measures can give a large increase in power. However,
in the more realistic situation with unknown parameters, the literature on posterior predictive
p-values suggests to estimate the parameters under the null hypothesis. Conditioning on the null-
hypothesis is motivated by the need for obtaining a valid test under the null. However, under a true
alternative, imputation of compliance statuses would then be conducted under the wrong model
which could result in a loss of power to detect a non-zero CACE. The intuition is that there might
be scenarios where the distributions of outcomes for compliers and never-takers under active and
control treatment assignment are such that in the control arm units imputed as compliers from
the posterior distribution conditional on the null hypothesis end up being the ones with outcomes
close to the compliers in the treatment group, resulting in small values of the observed complier
average causal effect, i.e., D(Y obs,Dobs,Zobs). This potential problem motivated us to investigate
an imputation of the compliance statuses from the posterior distribution p(C | Y obs,Dobs,Zobs)
without imposition of the null as an alternative. This is akin to a “plug-in” style approach in
classical testing. However, due to the same trade-off mentioned earlier, this relaxation could lead
to an increase in type I error, possibly giving an invalid test. We will also investigate how the use
of observed covariates, when available, can improve the imputation and thus the performance of
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p-values under either approach.
Given these tensions, we conducted a simulation study in order to assess whether these trade-
offs indeed occur, and in order to provide clear recommendations on what is best procedure. In
particular, we wish to compare the overall accuracy of discrepancy-based and statistic-based FRT-
PP under different compliance imputation models.
4 Simulation Study
Our simulation study is designed to assess the performance of different types of randomization-
based p-values in testing the sharp null hypothesis of no treatment effect for compliers, i.e., H0 :
Yi(0) = Yi(1) ∀i : Ci = 1, under the exclusion restriction assumption, i.e., Yi(0) = Yi(1)∀i : Ci = 0.
Specifically, we compared p-values from (5) using the test statistic in (9) and p-values from (8)
based on the discrepancy variable in (10). We also used four different methods for imputing the
compliance status in the control arm:
Imputation method 1: impute imposing the null hypothesis without including covariates, that is,
use the posterior distribution p(C | Y obs,Dobs,Zobs, H0)
Imputation method 2: impute without imposing the null hypothesis and without including covari-
ates, that is, use the posterior distribution p(C | Y obs,Dobs,Zobs)
Imputation method 3: impute imposing the null hypothesis and including covariates, that is, use
the posterior distribution p(C | Y obs,Dobs,Zobs, H0,X)
Imputation method 4: impute without imposing the null hypothesis and including covariates, that
is, use the posterior distribution p(C | Y obs,Dobs,Zobs,X)
The resulting eight testing methods were assessed under 3 × 7 × 2 scenarios defined by the level
of predictiveness of covariates on the compliance status (none, medium, high), by seven values of
the difference between the outcome mean under control assignment for compliers and never-takers,
i.e. E[Yi(0)|Ci = 1] − E[Yi(0)|Ci = 0], and by two values (0 for simulations under H0 and 0.5 for
simulations under H1) of a constant complier causal effect, i.e., we set the difference Yi(1)− Yi(0)
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between the outcomes for all compliers. For each simulation, performance was assessed as the
rejection rate at significance level α, which corresponds to either power or type I error.
4.1 Data Generating Process
In all of the simulation sets, we assumed a population of N=500 units posessing a single covariate
Xi ∼ N (0, 1). We generated the data and completely randomized NT = 250 to the treatment with
Zobsi = 1 and NC = 250 units to control with Z
obs
i = 0. The compliance status follows a probit
model conditional on the covariate Xi:
Ci = 1{α0 + αxXi + i > 0} i ∼ N (0, 1) (11)
where the coefficient vector α = [α0, αx] is varied to result in three different levels of predictiveness:
none (α = [−0.8, 0]), medium (α = [−1.4, 2]), high (α = [−2.8, 5]). The probability of being a
complier is then Φ(α0 +αxXi), where Φ(·) is the standard normal cumulative function. The values
of α0 are chosen such that pic = 0.30, that is, the overall proportion of compliers is always 30%.
The outcome follows a normal distribution with unitary variance and a mean that depends on the
compliance status and the scenario:
Yi(0) ∼

N (ηn, 1) if Ci = 0
N (ηc0, 1) if Ci = 1
Yi(1) =

Yi(0) if Ci = 0
Yi(0) + τ if Ci = 1
τ =

0 under H0
0.5 under H1
with ηn = 0 and ηc0 = {−3,−2,−1,−0.5, 0, 0.5, 1, 2, 3}.
The observed outcome is then given by: Y obsi = Yi(1)Z
obs
i + Yi(0)(1 − Zobsi ). In order to have a
better control on the overlap between the distributions of the two potential outcomes for never-
takers and compliers, we chose to model the outcome as independent from the covariates, even in
the two scenarios when these are predictive of the compliance status. In scenarios where covariates
do affect the outcome, if the individual treatment effect does not depend on covariates then our
results should not vary.
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4.2 Bayesian Inference for Imputation of Compliance Statuses
The computation of posterior predictive p-values is performed using an MCMC approach as ex-
plained in Section 3. Each iteration comprises an imputation and a permutation step. During the
imputation step unknown compliance statuses are drawn from the predictive posterior distribu-
tion p(C | Y obs,Dobs,Zobs), with an additional conditioning on H0 and covariates depending on
the method used. Because the parameters of this distribution are unknown, the predictive poste-
rior distribution of interest has to be averaged over the posterior distribution of the parameters:
p(C | Y obs,Dobs,Zobs) = ∫ p(C | Y obs,Dobs,Zobs,θ)p(θ | Y obs,Dobs,Zobs)dθ. In practice, it is
often convenient to make use of a two-stage Gibbs-sampler, which samples the parameters from
their full conditional distribution p(θ | Y obs,Dobs,Zobs,C) and then samples the vector of com-
pliance statuses from p(C | Y obs,Dobs,Zobs,θ). This algorithm is known as data augmentation
(Tanner & Wong, 1987). In this simulation study, Bayesian inference is based on correct model
specification. The only misspecification comes from conditioning on the null hypothesis for methods
1 and 3. Therefore we used the model for the compliance status from (11) and the following model
for potential outcomes
Yi(0)|Ci = 1 ∼ N (ηc1, σc)
Yi(0)|Ci = 0 ∼ N (ηn, σn)
Yi(1)|Ci = 1 ∼ N (ηc1, σc)
Yi(1)|Ci = 0 ∼ N (ηn, σn)
with means and variances following from exclusion restriction. At each iteration k, after the pa-
rameters are drawn from their posterior, the unknown compliance status for units in the control
group is imputed as follows:
Pr(Ci = 1|Y obsi , Zi = 0, Xi,θ) =
φ(Y obsi ; ηc, σc)Φ(α0 + αxXi)
φ(Y obsi ; ηc, σc)Φ(α0 + αxXi) + φ(Y
obs
i ; ηn, σn)(1− Φ(α0 + αxXi))
(12)
For imputation methods 1 and 3, we impose the null hypothesis for imputing the compliance
status by assuming ηc0 = ηc1 = ηc in the Bayesian estimation of the parameters. Similarly, we
set αx = 0 for imputation methods 1 and 2, where we do not take covariates into account. We
used conjugate prior distributions for the normal model with unknown variance, that is, normal
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distributions for the means and inverse gamma distributions for the variances:
ηc, ηc0, ηc1, ηn ∼ N (0, 10) σc, σn ∼ IG(0.1, 0.1)
4.3 Simulation Procedure
For the eight testing methods defined by the imputation method and the use of test statistic or
discrepancy variable, we, for each of the 3× 7× 2 scenarios, repeated the following 2000 times:
1. Generate a randomized sample of N units from the distributions outlined in the generating
process (with specific values of α and ηc0 and assuming the null (τ = 0) or the alternative
hypothesis (τ = 1), resulting in (Zobs,X,C,Y obs);
2. Calculate posterior predictive p-values using the test statistic or the discrepancy measure via
the following steps:
(a) Impute the compliance statuses C˜i for units in the control group using one of the four
imputation methods. This step is performed by the following two-stage Gibbs-sampling
procedure:
i. Draw a value of the parameters from their posterior distribution, which depends on
the imputation method.
ii. Use equation (12) with the drawn parameters to impute the compliance statuses for
units in the control group.
(b) Compute the observed test statistic T (Y obs,Dobs,Zobs) or the ‘observed’ discrepancy
measure D(Y obs, C˜,Zobs).
(c) Take a random sample from the set of all possible assignment vectors Z.
(d) Compute the test statistic T (Y obs, C˜Z,Z) or discrepancy measure D(Y obs, C˜,Z), based
on the imputed compliance statuses and the sampled assignment vector.
(e) Compare this test statistic or discrepancy measure with the observed value and output
1 if the new value is larger than the observed and 0 otherwise.
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(f) Repeat steps (a)-(e) K = 2000 times and average the outputs of the last 1000 iterations
(1000 discarded as burn-in) to get the nominal p-values.
Note that we do not need to do a full permutation on the inner loop as the expected value of the
single comparison will be that conditional p-value. Averaging these “estimates” over the 1000 trials
gives our desired overall expectation.
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Figure 1: Type I error and power for level of significance α = 0.05 against ηc0 − ηn, for
both test statistics (left) and discrepancy variables (right) with zero predictiveness of the co-
variates. The four lines represent the four different methods of imputation of compliance sta-
tus: p(C | Y obs,Dobs,Zobs, H0) (solid blue line), p(C | Y obs,Dobs,Zobs) (solid red line),
p(C | Y obs,Dobs,Zobs, H0,X) (dashed blue line), p(C | Y obs,Dobs,Zobs,X) (dashed red line).
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5 Results
To compare the validity and power of the Bayesian FRT for each method, we computed the rejection
rates for a test with level α = 0.05 for simulations conducted under the null hypothesis and
the alternative hypothesis, respectively. Figure 1 shows results when the compliance status does
not depend on covariates. For each imputation method and for both the test statistic and the
discrepancy variable, we plot the estimated Type I error and power, based on 2000 simulations,
against ηc0 − ηn, the difference between complier and never-taker means.
Posterior predictive p-values based on the test statistic appear to be unaffected by the imputa-
tion methods. In principle the test statistic depends on the imputed compliance statuses through
the corresponding proportion of compliers pˆic. Nevertheless, this quantity is robust to model mis-
specification, given that, thanks to randomization, Pr(Ci = 1) = Pr(Di = 1|Zi = 1). Therefore,
Bayesian tests based on this test statistic appear to have a size around the nominal level for any
imputation method and for any distance between compliers and never-takers in the control group.
In fact, histograms of the distributions of such p-values (not shown) suggest a uniform distribu-
tion. The power of these tests, however, decreases as ηc0 − ηn gets larger. This occurs because the
variance of ÎTT Y depends on the difference in outcomes between compliers and never-takers.
Unlike test statistic p-values, discrepancy-based p-values are very sensitive to the compliance
imputation method, given that at each iteration the discrepancy measure assumes the imputed com-
pliance status for every unit as the true status. As expected, when imputing conditional on the null
hypothesis, the test is conservative with a Type I error around 0.01. Also as hypothesized, when out-
comes for compliers and never-takers in the control group are close, the use of discrepancy variables
fails dramatically to reject a false null hypothesis under the alternative. The difficulty in disentan-
gling the mixture between never-takers and compliers when these have similar outcomes, in com-
bination with the exclusion restriction assumption (implying E{Yi(0)|Ci = 0} = E{Yi(1)|Ci = 0})
and the null hypothesis (implying E{Yi(0)|Ci = 1} = E{Yi(1)|Ci = 1}), leads to an overestimation
of the mean ηc0 for control compliers and, as a consequence, units in the control group imputed as
compliers tend to have outcomes that are closer to those for treated compliers. In particular, when
ηc0 − ηn = 0 or −0.5 the power of the test goes to zero.
18
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Figure 2: Type I error and power for level of significance α = 0.05 against ηc0 − ηn, for
both test statistics (left) and discrepancy variables (right) with medium predictiveness of the
covariates. The four lines represent the four different methods of imputation of compliance
status: p(C | Y obs,Dobs,Zobs, H0) (solid blue line), p(C | Y obs,Dobs,Zobs) (solid red line),
p(C | Y obs,Dobs,Zobs, H0,X) (dashed blue line), p(C | Y obs,Dobs,Zobs,X) (dashed red line).
Imputing with ηc0 and ηc1 unconstrained, i.e., imputing without conditioning on the null, par-
tially corrects this phenomenon. Under this alternate imputation strategy, the discrepancy-based
FRT-PP yields greater power than when imputing under the null, with a minimum of 51% when
ηc0 − ηn = 0. Moreover, the FRT-PP with an unconstrained imputation method also outperforms
test statistic-based p-values with an average gain in power of 30%. Unfortunately, this gain in power
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comes with a substantial price: there is a range of values for ηc0 − ηn where the test is invalid.
Other simulations (not shown) reveal that this loss in validity is even higher when the proportion
of compliers is lower.
The above is without any predictive covariate. We next examine whether improved prediction of
compliance status changes these patterns. Figure 2 shows results for the scenario where covariates
predict compliance status with a medium level of predictiveness. Performance of statistic-based
tests is similar to the previous case. Discrepancy variables, however, are more robust: the problem
of invalid tests when imputing the compliance statuses without imposing the null is attenuated.
Furthermore, when covariates are used as predictors of the compliance status in the imputation
step, power can greatly increase for all discrepancy-based methods. These improvements in validity
and power are even more visible when the level of predictiveness of the covariates is higher, as shown
in Figure 3.
6 Comparison with Model-based Tests
As we have seen, the FRT-PP methods based on discrepancies heavily rely on the imputation model.
The advantage of Fisher randomization tests as model-free tests is then somewhat lost. Averaging
Fisher randomization p-values over the predictive posterior distribution of the compliance status
depends on a posterior predictive distribution that, in turn, depends on the posterior distribution
of the model parameters. Given this, one might think of just relying on the posterior distribution
of the parameters, which in this case would be ηc1 − ηc0. Model-based p-values for testing a
zero treatment effect would then be Pr{ηc1 − ηc0 ≥ 0|Y obs,Dobs,Zobs,X}. Using these Bayesian
model-based p-values to test the null hypothesis is arguably model-dependent, but so is the FRT-PP
based on discrepancies. The direct Bayesian approach thus seems superior as it does not require a
permutation step making it less computationally demanding as well as more transparent.
On the other hand, such a model-based test could be relying more heavily on model assumptions
than the FRT-PP approach, given that it strictly depends on good estimation of both ηc1 and ηc0.
By contrast, in one-side noncompliance FRT-PP does not directly depend on the estimation ηc1, and
only uses ηc0 and ηn indirectly to impute compliance statuses in the control group. Consequently,
20
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Figure 3: Type I error and power for level of significance α = 0.05 against ηc0 − ηn, for
both test statistics (left) and discrepancy variables (right) with high predictiveness of the co-
variates. The four lines represent the four different methods of imputation of compliance sta-
tus: p(C | Y obs,Dobs,Zobs, H0) (solid blue line), p(C | Y obs,Dobs,Zobs) (solid red line),
p(C | Y obs,Dobs,Zobs, H0,X) (dashed blue line), p(C | Y obs,Dobs,Zobs,X) (dashed red line).
we might expect model misspecification to affect model-based p-values more severely. We explore
this under an extreme case of misspecification, that is, when we impose the assumption that the
outcome mean under treatment is the same for compliers and never-takers in the estimation step:
E[Yi(1)|Ci = 0] = E[Yi(1)|Ci = 1] (13)
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Figure 4: Type I error and power for level of significance α = 0.05 against ηc0 − ηn, for FRT-
PP based on discrepancy variables and model-based tests with low predictiveness of the covari-
ates. The six lines represent FRT-PP with the four different methods of imputation of compli-
ance status, p(C | Y obs,Dobs,Zobs, H0) (solid blue line), p(C | Y obs,Dobs,Zobs) (solid red line),
p(C | Y obs,Dobs,Zobs, H0,X) (dashed blue line), p(C | Y obs,Dobs,Zobs,X) (dashed red line),
and model-based tests not including and including covariates in the compliance model (solid green
and dashed green lines, respectively).
This assumption might be plausible in different situations. An example is when never-takers do not
take treatment due to access to some other, similar, treatment that we do not see. Imposing this
assumption when it is not true will compromise the estimation of ηc1 and ηn, which will indirectly
impact the estimation of ηc0.
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Figure 4 compares the Type I error and power of discrepancy-based FRT-PP tests and model-
based tests under this misspecification when compliance status is not predicted by covariates.
First, when we have correct model specification, model-based tests have the same performance as
discrepancy-based FRT-PP using an unconstrained imputation method, as illustrated by the top
row of Figure 4. Note the overlapping lines corresponding to the model-based approach and the
unconstrained imputation approach with and without covariates (imposing the null results in a
reduction of rejection rates across the board).
Under the misspecification induced by Assumption 13, however, performance patterns diverge.
This is the bottom row of Figure 4. The validity of model-based tests is compromised when ηc0 < ηn
because ηc1, which should be equal to ηc0 under the null, is instead assumed to be equal to ηn. When
ηc0 − ηn = −3 false rejection rate gets as high as 100% for the model-based method. Discrepancy-
based tests also do not fare well, however. For the methods with imputation under the null, if
ηc0 − ηn < 0 validity is preserved but power is wiped out . As ηc0 − ηn grows increasingly positive,
rejection rates jump regardless of whether the null is true or not. Overall, imposing assumption 13,
together with the exclusion restriction for never-takers and the null hypothesis, leads to a complete
failure of the discrepancy-based FRT-PP that impute compliance statuses in the control group
conditioning on the null.
When imputing without imposing the null, the pattern is somewhat irregular. For ηc0− ηn < 0
under the null, the size of the tests becomes conservative for a low difference between compliers and
never-takers and then increases as the difference gets higher. This is due to an underestimation
of ηc0 when ηc0 − ηn << 0. Conversely, when ηc0 − ηn > 0, the size of the tests increases for
a low difference and decreases as the difference gets higher. The size of these tests, while under
the nominal level when ηc0 − ηn ≤ 0, jumps immediately out of the range of validity when the
outcome mean for compliers is greater than the one for never-takers. None of the tests perform
well under this misspecification. When comparing the left and right sides, the pattern of rejection
rates appears to be more about the value of ηc0 − ηn than the actual hypothesis being tested.
Figure 5 and Figure 6 compares the model-based and FRT-PP approaches under medium and
high predictiveness, respectively. Under correct specification (i.e., when 13 is not imposed) model-
23
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Figure 5: Type I error and power for level of significance α = 0.05 against ηc0 − ηn, for FRT-PP
based on discrepancy variables and model-based tests with medium predictiveness of the covari-
ates. The six lines represent FRT-PP with the four different methods of imputation of compli-
ance status, p(C | Y obs,Dobs,Zobs, H0) (solid blue line), p(C | Y obs,Dobs,Zobs) (solid red line),
p(C | Y obs,Dobs,Zobs, H0,X) (dashed blue line), p(C | Y obs,Dobs,Zobs,X) (dashed red line),
and model-based tests not including and including covariates in the compliance model (solid green
and dashed green lines, respectively).
based tests still have the same performance as discrepancy-based FRT-PP using an unconstrained
imputation method, with and without the use of covariates. When model parameters are estimated
under assumption 13, model-based and discrepancy-based FRT-PP are affected as previously, when
covariates are not included in the compliance model. The use of compliance-predictive covariates
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improves validity and reduces the power loss for all tests. Nevertheless, even with a high level
of predictiveness, both model-based tests and discrepancy-based FRT-PP imposing the null still
have very low performance for wide ranges of values. The use of covariates does not always ensure
validity for discrepancy-based FRT-PP that do not impose the null. In fact, when ηc0−ηn ∈ {0.5, 2}
the size of these tests is still higher than 15%, well above the nominal α = 0.05. That being said,
these results also do suggest that unconstrained discrepancy-based FRT-PP can be more robust to
model misspecification than both model-based tests and discrepancy-based FRT-PP conditioning
on the null. In particular, they do not suffer the of complete invalidity as the other approaches
(peaking at 60% Type I error vs. the others achieving near 100% error rates), while maintaining a
generally higher level of power under the alternative.
7 Concluding Remarks
Fisher randomization tests (FRTs) are concerned with testing hypothesis regarding the effect of
treatments. By exploiting the known assignment mechanism, they work simply by enumerating all
possible values of a specified test statistic under the null hypothesis and comparing this distribution
to the observed value. In noncompliance settings, one can impute the unknown compliance statuses
with a Bayesian framework and conduct randomization tests with the complete data. The resulting
FRT-PP then averages over the posterior distribution of the unknown compliance statuses. Here, we
compared the use of discrepancy measures to classical test statistics within this framework. Being
parameter-dependent, discrepancies more heavily depend on the imputation model, including the
imposition of the null hypothesis. We investigated the resulting trade-off between the size and the
power of the test.
Discrepancy-based FRT-PP that use an imputation method under the null are fairly conser-
vative, and are generally valid testing procedures. Unfortunately, however, we found situations
where misclassification of compliers and never-takers, due to imposing the null, led to a severe
reduction of power. This problem can be overcome by using an unconstrained imputation method,
which on average achieves higher power than both discrepancy-based FRT-PP under the null and
statistic-based FRT-PP. Unfortunately, this unconstrained imputation can result in invalid tests,
25
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Figure 6: Type I error and power for level of significance α = 0.05 against ηc0 − ηn, for FRT-
PP based on discrepancy variables and model-based tests with high predictiveness of the covari-
ates. The six lines represent FRT-PP with the four different methods of imputation of compli-
ance status, p(C | Y obs,Dobs,Zobs, H0) (solid blue line), p(C | Y obs,Dobs,Zobs) (solid red line),
p(C | Y obs,Dobs,Zobs, H0,X) (dashed blue line), p(C | Y obs,Dobs,Zobs,X) (dashed red line),
and model-based tests not including and including covariates in the compliance model (solid green
and dashed green lines, respectively).
even in scenarios where the model is correctly specified.
With regard to the use of test statistics, the size of the test stayed close to the nominal levels for
all scenarios. Power decreases as the outcomes for compliers in the control group move away from
those for never-takers, but is, on average, greater than the one given by discrepancy-based FRT-
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PP assuming the null. Overall, our test statistic, compared to our discrepancy measure, seems
less affected by the imputation method. The test statistic, in fact, depends on the imputation
model only through the estimated proportion of compliers. As a natural consequence, statistic-
based tests are expected to be more robust to model misspecification as long as the proportion of
imputed compliers is not significantly compromised.
Discrepancies depend tremendously on the imputation method and can be largely affected
by model misspecification. Therefore, as a recommendation for practitioners, if the model is likely
misspecified (e.g., important covariates are missing, measures of goodness of fit are not satisfactory,
etc.) then use FRT-PP based on test statistics, not discrepancy measures, to maintain validity.
That being said, if we are confident in our posited model, the use of discrepancy-based tests could
in principle improve power. This is not always the case if the imputation is performed under the
null, as this method can oftentimes lead to a large loss of power. For the purpose of power gain,
imputation methods that do not impose the null hypothesis seem to be more appropriate, save
for the serious concern of an elevated risk of validity. The use of predictive covariates, if present,
does attenuate this risk as well as it does increase power for either imputation method. Overall,
with a high or medium level of predictiveness, we recommend leaving the imputation method
unconstrained.
As a final investigation, we compared the discrepancy-based FRT-PP method to full Bayesian
model-based testing. We found that a model-based test was comparable to a discrepancy-based
test that does not impose the null hypothesis. However, the latter FRT-PP method was more
robust to misspecification, giving evidence that the additional permutation step can somewhat
protect a researcher from model specification issues when doing inference. These simulations are
for a specific class of data generation processes, and further work needs to be done to more fully
understand this novel form of statistical inference. Certainly there are substantial dangers in taking
these approaches, but there is also evidence that there is a lot to be gained.
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